Products - Headaches | Topic | NICE

Showing 12 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Atogepant for preventing migraine (TA973)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 May 2024
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012
Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)
Product type:
Guidance
Programme:
NICE guideline
Published:
7 April 2021
Eptinezumab for preventing migraine (TA871)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 March 2023
Erenumab for preventing migraine (TA682)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 March 2021
Fremanezumab for preventing migraine (TA764)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Galcanezumab for preventing migraine (TA659)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 November 2020
gammaCore for cluster headache (HTG533)
Product type:
Guidance
Programme:
HealthTech guidance
Published:
3 December 2019
Headaches in over 12s: diagnosis and management (CG150)
Product type:
Guidance
Programme:
Clinical guideline
Last updated:
3 June 2025
Published:
19 September 2012
Rimegepant for preventing migraine (TA906)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 July 2023
Rimegepant for treating migraine (TA919)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 October 2023
Suspected neurological conditions: recognition and referral (NG127)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 October 2023
Published:
1 May 2019